Earlier this week on November 16, HDSA launched applications for the 2022 cycles of its prestigious Berman-Topper Family HD Career Development Fellowship and Donald A. King Summer Research Fellowship. To learn more about these exciting opportunities and how to apply, visit the Berman-Topper Fellowship and Donald A. King Fellowship pages on HDSA’s website.
Prilenia Therapeutics Receives Fast-Track Designation for Pridopidine for Treatment of HD
Prilenia Therapeutics announced yesterday that the US FDA has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s disease. This designation is reserved to speed up development and review of experimental medications that have the potential to improve treatment options for dire health conditions and fill unmet medical needs.
As HDBuzz reported in June of this year, pridopidine is a highly selective sigma 1 receptor (S1R) agonist. S1R proteins are found in brain regions affected by HD, and help nerve cells survive under stress. Pridopidine targets S1R proteins to help improve the brain’s response to stress brought on by HD. Fast Track designation will provide Prilenia the opportunity to collaborate with the FDA for comprehensive development of pridopidine for treatment of HD.
Physical Activity in HD—Actividad Física en la Enfermedad de Huntington
Earlier this week, movement expert, Dr. Gregory Youdan, was joined by Dr. Lola Diaz from Neurogen Research Foundation for a discussion on physical activity in Huntington’s Disease. To view the recorded presentation, given in Spanish, click here.
A principios de esta semana, el experto en movimiento, Dr. Gregory Youdan, se unió a la Dr. Lola Diaz de la fundación de investigación, NeuroGen, para una conversación sobre la actividad física en la Enfermedad de Huntington. Para ver la presentación, haga clic aquí.
